Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Mayne buys back US Doryx rights from Actavis for $50mm

01 Jun 2021

Executive Summary

Actavis PLC divested to Mayne Pharma Group Ltd. its US rights to the tetracycline antibiotic Doryx (delayed-release doxycycline) for severe acne. Mayne, which originally developed the drug, paid $50mm and also gets the product's trademark, marketing materials, inventory, and medical and technical data.

Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By